[PRESS RELEASE] – ROCKVILLE, Md., Aug. 6, 2025– Upling, the leading high-speed medical cannabis delivery app, announced plans to officially launch Bud-E, a groundbreaking AI-powered cannabis genetics tool—an innovative feature designed to help patients identify cannabis strains best suited to their individual health needs.
Currently in beta testing, Bud-E leverages patient-reported outcomes, medical history, and optional genetic information to generate personalized, science-based strain recommendations using artificial intelligence. A full launch is planned for October.
“By combining personal health data, patient feedback, and genetic insights, our platform transforms cannabis from a trial-and-error process into one grounded in science,” said Colin Fraser, founder of Upling, the first Black-owned delivery-focused cannabis app. “Whether someone is managing PTSD, chronic pain, or insomnia, this tool takes the guesswork out and brings a precision medicine approach to cannabis care.”
With this release, Upling becomes one of the first cannabis delivery platforms to integrate advanced personalization technology directly into the user experience. Bud-E is designed to align with the company’s broader mission: connecting people with the right products, information, and support at every step of their wellness journey.
“I built Upling after watching my mother struggle to access medication during her cancer treatment,” Fraser said. “Implementing AI to curate cannabis consumption is a natural extension of that mission, removing barriers from the entire process so that patients feel supported from start to finish.”
In recent years, delivery has become a major driver of the legal cannabis industry’s growth. According to the U.S. Department of Health and Human Services, the number of registered medical cannabis patients rose by 37% from 2021 to 2023, fueling the demand for more accessible, patient-centered services. The Centers for Disease Control and Prevention reported that nearly 50% of medical cannabis patients prefer home delivery.
Bud-E will initially be available to medical cannabis patients in Upling’s Washington, D.C., and Maryland service areas, with plans to expand to adult-use customers in the future.
